Diamyd Medical - Developing precision therapies for type 1 diabetes

Press Releases

October 12, 2021

Clinical results with Diamyd Medical’s study drug Remygen^® published in scientific journal

Events & Mediawatch

October 13, 2021 Sweden

Insight Direkt: intervju med vd Ulf Hannelius med anledning av bokslutskommunikén

Calendar

Data pager
Data pager
1 2

October 18 − October 22, 2021

ASHG 2021 Virtual Meeting

Professional Development and Industry Forum

November 9 − November 10, 2021

Biomarkers for Rare Diseases

November 25, 2021

Erik Penser Bank Corporate Market Day

December 2, 2021

Annual General Meeting

Annual General Meeting 2020/2021

December 6 − December 11, 2021

IDF Virtual Congress 2021

International Diabetes Federation Virtual Congress

Financial Reports

October 13, 2021
Year-End Report 20/21

Company Presentation

June 23, 2021

We will make sure to work closely with the FDA and other authorities to advance Diamyd^® as fast as possible.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Year-End Report 20/21, October 13, 2021

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 463 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research

ORDER

©

Privacy Policy | Cookie Policy

Share This Page

GAD PRODUCTS

Order GAD for preclinical research